Testolone (RAD-140): Mechanism and Pharmacology
Testolone is a non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health for potential use in muscle-wasting conditions and hormone-receptor-positive breast cancer. Chemically classified as a triazine derivative, RAD-140 distinguishes itself from other SARMs through an exceptionally high binding affinity for the androgen receptor (AR), with a Ki value reported in the low nanomolar range — comparable to testosterone itself, yet without direct androgenic activity in peripheral tissues such as the prostate. Testolone binds the androgen receptor with a selectivity profile that preferentially activates anabolic signalling pathways in skeletal muscle and bone while producing significantly attenuated stimulation in androgenic tissues, which is the pharmacological property that defines its appeal in research and sports supplementation contexts.
Once RAD-140 occupies the androgen receptor, it induces a distinct conformational change in the receptor's ligand-binding domain, recruiting specific coactivator proteins — notably SRC-1 and GRIP-1 — that drive transcription of anabolic genes including those governing myosin heavy-chain synthesis and satellite-cell proliferation. This tissue-selective transcriptional activation is the core mechanism separating SARMs from classical anabolic steroids, which trigger AR activation indiscriminately across tissues.
Oral bioavailability for RAD-140 is estimated to be high relative to many peptide-based compounds, attributed to its small, lipophilic molecular structure that resists first-pass hepatic clearance effectively. The plasma half-life in preclinical models has been measured at approximately 60 hours, suggesting that even once-daily dosing maintains stable serum concentrations — a practical advantage over compounds requiring split administration. Crucially, RAD-140 does not convert to dihydrotestosterone (DHT) via 5-alpha reductase activity, nor does it aromatise into oestrogen via aromatase, removing two of the most commonly cited side-effect pathways associated with exogenous testosterone use. Hypothalamic-pituitary-testicular axis (HPTA) suppression remains a documented pharmacological consequence, though the degree and reversibility are considered less severe than with full anabolic androgens in human case studies and animal models to date.
Application Context and User Groups
Within structured bodybuilding and physique sports, Testolone has attracted serious interest across several distinct user profiles. Advanced natural competitors seeking lean tissue accretion without the virilisation, oestrogen-mediated water retention, or hepatotoxicity typical of oral anabolic steroids represent one prominent cohort. RAD-140's anabolic-to-androgenic ratio has been cited in preclinical literature at approximately 90:1 when benchmarked against testosterone, a figure that circulates widely in sports science discussions as a shorthand for its preferential muscle-building profile.
Athletes in strength and power sports value Testolone during both accumulation phases and recomposition cycles. Its ability to support lean mass retention during a caloric deficit — without the catabolic pressure that accompanies natural testosterone suppression — makes it a compound of interest for those transitioning between off-season and pre-competition training. Endurance-oriented athletes have also reported subjective improvements in training capacity and recovery speed, consistent with RAD-140's demonstrated neuroprotective properties in preclinical research, which suggest partial involvement in neuronal AR signalling as well as peripheral anabolic pathways.
Experienced SARMs users frequently position RAD-140 as a standalone compound in moderate-duration protocols lasting 8 to 12 weeks, or incorporate it as a component in more complex stacks. It pairs commonly with other non-aromatising SARMs for synergistic receptor-level effects. Users with experience of traditional androgen use often note that RAD-140's effects — in terms of both muscle fullness and strength output — are subjectively more pronounced than those produced by lighter SARMs such as Ostarine, yet the absence of oestrogen-related side effects remains the chief differentiator from testosterone-based cycles. Post-cycle support to facilitate HPTA recovery is routinely employed by informed users following any RAD-140 protocol.
Women in physique sports represent a smaller but growing segment, attracted by RAD-140's anabolic potency without the virilisation risk inherent to even low-dose testosterone. Given the compound's potency, female users typically operate at the lower end of the available concentration range and shorter cycle durations.
Range and Selection by Concentration and Pack Size
Our Testolone category currently offers two distinct products across two concentration tiers — 10 mg per tablet and 15 mg per tablet — providing flexibility for users across the experience spectrum.
Testolone (RAD140) 10mg/tab 60 Tablets by Elbrus Pharmaceuticals is the entry point in this range and the logical starting choice for those new to RAD-140 or returning after an extended break. At 10 mg per tablet across a 60-tablet pack, this format provides a 6-week supply at a standard 10 mg daily protocol, or extends to a full 8-week run for those who choose to taper or alternate dosing on their opening cycle. Elbrus Pharmaceuticals' pharmaceutical-style tablet production is consistent with the brand's broader commitment to accurate dosing and stability across its SARM catalogue. The 10 mg tier suits users who wish to assess individual response before committing to higher daily intake, and it offers granular control for those stacking Testolone with other compounds where total androgen receptor stimulation must be managed carefully.
Testolone 15mg/tab 50 Tablets by Rich Piana 5% Nutrition occupies the upper concentration tier and is tailored for experienced users who have already established their tolerance to RAD-140 at the standard 10 mg dose. At 15 mg per tablet, this format is better suited to advanced protocols where enhanced daily receptor occupancy is the objective — particularly during recomposition or strength-focused blocks where maximum anabolic drive is prioritised. The 50-tablet pack, used at 15 mg daily, provides approximately a 7-week supply, aligning well with typical 6-to-8-week advanced cycles. Rich Piana 5% Nutrition brings its established brand identity — directness, high-performance positioning, and a loyal following in the competitive bodybuilding community — to the SARM segment, and the 15 mg tablet represents a deliberate step beyond entry-level dosing.
Choosing between these tiers should be guided by prior SARM experience, current cycle complexity, and individual sensitivity rather than a simple preference for higher milligram values. Both concentrations deliver the same active compound; the difference lies in the precision of dose management and the risk-to-benefit calibration each user applies to their own protocol.
Frequently Asked Questions
What is the recommended daily dose of Testolone (RAD-140) for bodybuilding purposes?
Most experienced users report protocols ranging from 10 mg to 20 mg per day, with 10 mg considered a well-tolerated starting dose and 15 mg a common intermediate target. Cycles typically run 8 to 12 weeks. Individual response varies significantly, and starting at the lower end of the available concentration range is the standard informed approach before escalating.
Does Testolone (RAD-140) require post-cycle therapy?
Yes. RAD-140 suppresses endogenous testosterone production through HPTA feedback inhibition, particularly at higher doses and longer cycle durations. Post-cycle support using established recovery agents is widely recommended by experienced users to restore natural hormone output. The degree of suppression is generally considered dose- and duration-dependent, making cycle length management an important variable.
How does RAD-140 differ from other SARMs like Ostarine or Ligandrol?
RAD-140 is generally regarded as more potent than Ostarine in terms of anabolic drive, with a more pronounced impact on lean muscle accretion and strength. Compared to Ligandrol (LGD-4033), RAD-140 offers a similar lean mass profile but with a broader anecdotal neuroprotective reputation. Its reported 90:1 anabolic-to-androgenic ratio makes it one of the strongest-profiled compounds in the SARM class.
Lab Tested
